Irwin Mitchell: Irwin Mitchell is proud to be a longstanding corporate supporter of Group B Strep Support.
Through our work, we often see the outcomes from late diagnosis or treatment for GBS. As a result, we campaign for testing during pregnancy, and to prevent the early onset of GBS infection.
We understand the importance for both families and healthcare professionals of having access to good quality information about group B Strep. We’re committed to supporting the valuable work of Group B Strep Support by raising awareness, and helping to work towards better outcomes for all.
Cepheid: Over a decade ago, Cepheid set the standard for innovation in automated molecular diagnostics — and we’ve never looked back. The GeneXpert® System has been heralded as game-changing by healthcare leaders across the globe — enabling institutions of any size, from small medical clinics to high-volume reference laboratories and hospitals, to access the speed and accuracy of molecular diagnostics. Cepheid’s growing Xpert® test menu spans multiple clinical applications including healthcare-associated infections, sexual health, critical infectious disease, virology, and oncology.
LabReady®: LabReady® is a healthcare technology company redefining the 85-year old specimen collection process–leading to faster, more reliable diagnoses. LabReady® GBS is the world’s first enriched rapid test for diagnosing Group B Strep infections in the provider’s office or at-home without need for a lab.
LabReady® GBS will launch in the UK and the EU in late 2021.
Leigh Day: Leigh Day is a specialist law firm acting exclusively for claimants. We have one of the largest and most experienced teams of medical negligence lawyers.
We have unrivalled experience in running complex and challenging medical negligence cases, and are ranked by legal directories as national leaders in the field.
We have been successfully securing settlements for clients and campaigning for access to justice and patient safety issues for over 30 years.
Pfizer Vaccine Research & Development develops first-in-class and best-in-class vaccines against diseases of major public health importance that impact all ages and geographies. It is a fully integrated organization with responsibilities from the early-idea stage through clinical development, product registration and post-marketing commitments. Pfizer Vaccine R&D is applying leading-edge science towards helping fight Group B Streptococcus and other diseases and to bringing breakthrough prophylactic and viral vaccines to vulnerable people of all ages.
Phone: +1 (212) 733-2323
Minervax: MinervaX is developing a GBS vaccine based on a family of surface proteins found on 99.7% of clinical isolates. It is highly immunogenic, resulting in long-lasting high titres of functionally active antibodies. The vaccine has been tested in 300 healthy adult women and is currently being tested in pregnant women in Africa